Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novasep Invests In Drug Conjugates
by Rick Mullin
July 6, 2015
| A version of this story appeared in
Volume 93, Issue 27
The contract manufacturing organization (CMO) Novasep plans to build an antibody-drug conjugate (ADC) facility at its site in Le Mans, France. The $11 million project will enhance the company’s current ADC offering with what it calls full bioconjugation services. “Novasep is one of the few CMOs able to produce both commercial-scale ADC payloads and monoclonal antibodies,” says Thierry van Nieuwenhove, president of Novasep’s synthesis business unit. The company expects the facility to open by mid-2016.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter